NDUFA1 p.Gly32Arg variant in early-onset dementia |
|
Author: | Huttula, Samuli1,2; Väyrynen, Henri1,2; Helisalmi, Seppo3; |
Organizations: |
1Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland 2MRC, Oulu University Hospital, Oulu, Finland 3Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland
4Cancer and Translational Medicine Research Unit, Pathology, University of Oulu, Oulu, Finland
5Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland |
Format: | article |
Version: | published version |
Access: | open |
Online Access: | PDF Full Text (PDF, 0.3 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe2022101161573 |
Language: | English |
Published: |
Elsevier,
2022
|
Publish Date: | 2022-10-11 |
Description: |
AbstractEarly-onset dementia (EOD) is highly heritable. However, in many EOD cases the genetic etiology remains unknown. Mitochondrial dysfunction is associated with neurodegeneration and the complex I (CI) deficiency is the most common enzyme deficiency in diseases related to oxidative phosphorylation. The X-chromosomal NDUFA1 gene is essential for the activity of CI. Mutations in NDUFA1 are associated with mitochondrial diseases especially with Leigh syndrome. CI deficiency is also associated with neurodegenerative diseases, such as Alzheimer’s disease (AD). The aim of this study was to evaluate the role of NDUFA1 variants in EOD patients. Next-generation sequencing panel was used to screen NDUFA1 variants in a cohort of 37 EOD patients with a family history of dementia or an atypical or rapidly progressive course of disease. We identified a hemizygous p.Gly32Arg variant in two brothers with AD. Subsequent screening of the variant in a larger cohort of EOD patients (n = 279) revealed three additional variant carriers (one male and two heterozygote females), suggesting that NDUFA1 variant p.Gly32Arg may play a role in neurodegenerative dementia. see all
|
Series: |
Neurobiology of aging |
ISSN: | 0197-4580 |
ISSN-E: | 1558-1497 |
ISSN-L: | 0197-4580 |
Volume: | 114 |
Pages: | 113 - 116 |
DOI: | 10.1016/j.neurobiolaging.2021.09.026 |
OADOI: | https://oadoi.org/10.1016/j.neurobiolaging.2021.09.026 |
Type of Publication: |
A1 Journal article – refereed |
Field of Science: |
3112 Neurosciences 3124 Neurology and psychiatry 3111 Biomedicine |
Subjects: | |
Funding: |
This study was supported by the Academy of Finland [grant numbers 315460 (AMR), 307866 (MH) and 325022 (SHe)]; The University of Oulu Scholarship Foundation (SHu, LL, AMR); Orion Research Foundation (SHu); Sigrid Jusélius Foundation (MH, LK); The Strategic Neuroscience Funding of the University of Eastern Finland (MH) and Medical Research Center Oulu (LK). |
Academy of Finland Grant Number: |
315460 |
Detailed Information: |
315460 (Academy of Finland Funding decision) |
Dataset Reference: |
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.neurobiolaging.2021.09.026. |
http://dx.doi.org/10.1016/j.neurobiolaging.2021.09.026 |
|
Copyright information: |
© 2022 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) |
https://creativecommons.org/licenses/by/4.0/ |